Display options
Cite
Melka MG, Castellani CA, O'Reilly R, et al. Insights into the origin of DNA methylation differences between monozygotic twins discordant for schizophrenia. J Mol Psychiatry. 2015;3(1):7doi: 10.1186/s40303-015-0013-5.
Melka, M. G., Castellani, C. A., O'Reilly, R., & Singh, S. M. (2015). Insights into the origin of DNA methylation differences between monozygotic twins discordant for schizophrenia. Journal of molecular psychiatry, 3(1), 7. https://doi.org/10.1186/s40303-015-0013-5
Melka, Melkaye G, et al. "Insights into the origin of DNA methylation differences between monozygotic twins discordant for schizophrenia." Journal of molecular psychiatry vol. 3,1 (2015): 7. doi: https://doi.org/10.1186/s40303-015-0013-5
Melka MG, Castellani CA, O'Reilly R, Singh SM. Insights into the origin of DNA methylation differences between monozygotic twins discordant for schizophrenia. J Mol Psychiatry. 2015 Jun 26;3(1):7. doi: 10.1186/s40303-015-0013-5. eCollection 2015. PMID: 26137221; PMCID: PMC4487197.
Copy Download .nbib Format: NLM
Share it on

J Mol Psychiatry. 2015 Jun 26;3(1):7. doi: 10.1186/s40303-015-0013-5. eCollection 2015.

Insights into the origin of DNA methylation differences between monozygotic twins discordant for schizophrenia.

Journal of molecular psychiatry

Melkaye G Melka, Christina A Castellani, Richard O'Reilly, Shiva M Singh

Affiliations

  1. Molecular Genetics Unit, Western Science Centre, Department of Biology, The University of Western Ontario, London, Ontario N6A 5B7 Canada.
  2. Department of Psychiatry, The University of Western Ontario, London, Ontario N6A 5B7 Canada.

PMID: 26137221 PMCID: PMC4487197 DOI: 10.1186/s40303-015-0013-5

Abstract

BACKGROUND: DNA methylation differences between monozygotic twins discordant for schizophrenia have been previously reported. However, the origin of methylation differences between monozygotic twins discordant for schizophrenia is not clear. The findings here argue that all DNA methylation differences may not necessarily represent the cause of the disease; rather some may result from the effect of antipsychotics.

METHODS: Methylation differences in rat brain regions and also in two pairs of unrelated monozygotic twins discordant for schizophrenia have been studied using genome-wide DNA methylation arrays at Arraystar Inc. (Rockville, Maryland, USA). The identified gene promoters showing significant alterations to DNA methylation were then further characterized using ingenuity pathway analysis (Ingenuity System Inc, CA, USA).

RESULTS: Pathway analysis of the most significant gene promoter hyper/hypomethylation revealed a significant enrichment of DNA methylation changes in biological networks and pathways directly relevant to neural development and psychiatric disorders. These included HIPPO signaling (p = 3.93E-03) and MAPK signaling (p = 4.27E-03) pathways involving hypermethylated genes in schizophrenia-affected patients as compared to their unaffected co-twins. Also, a number of significant pathways and networks involving genes with hypomethylated gene promoters have been identified. These included CREB signaling in neurons (p = 1.53E-02), Dopamine-DARPP32 feedback in cAMP signaling (p = 7.43E-03) and Ephrin receptors (p = 1.13E-02). Further, there was significant enrichment for pathways involved in nervous system development and function (p = 1.71E-03-4.28E-02).

CONCLUSION: The findings highlight the significance of antipsychotic drugs on DNA methylation in schizophrenia patients. The unique pathways affected by DNA methylation in the two pairs of monozygotic twins suggest that patient-specific pathways are responsible for the disease; suggesting that patient-specific treatment strategies may be necessary in treating the disorder. The study reflects the need for developing personalized medicine approaches that take into consideration epigenetic variations between patients.

References

  1. Schizophr Res. 2014 Feb;152(2-3):373-80 - PubMed
  2. Schizophr Bull. 2003;29(1):169-78 - PubMed
  3. Eur Psychiatry. 2014 Mar;29(3):167-71 - PubMed
  4. Trends Genet. 2006 Jul;22(7):347-50 - PubMed
  5. Clin Genet. 2002 Aug;62(2):97-103 - PubMed
  6. Prog Mol Subcell Biol. 2005;38:151-67 - PubMed
  7. Neuropsychopharmacology. 2013 Feb;38(3):423-36 - PubMed
  8. J Hist Neurosci. 2013;22(1):62-78 - PubMed
  9. J Mol Psychiatry. 2013 Nov 04;1(1):19 - PubMed
  10. Biol Psychiatry. 2014 Dec 15;76(12):977-83 - PubMed
  11. Genes (Basel). 2014 May 05;5(2):347-65 - PubMed
  12. J Nutr Biochem. 2014 Apr;25(4):496-502 - PubMed
  13. Hum Mol Genet. 2010 Nov 1;19(21):4176-88 - PubMed
  14. Am J Med Genet B Neuropsychiatr Genet. 2004 May 15;127B(1):51-9 - PubMed
  15. BMC Med Genomics. 2015 May 06;8:17 - PubMed
  16. Psychiatry Res. 2012 Aug 15;198(3):533-7 - PubMed
  17. Epigenetics. 2014 Oct;9(10):1410-21 - PubMed
  18. Clin Epigenetics. 2014 Jan 02;6(1):1 - PubMed
  19. Encephale. 2014 Oct;40(5):380-6 - PubMed
  20. Neuropharmacology. 2011 Jun;60(7-8):1007-16 - PubMed
  21. Neuropharmacology. 2012 Mar;62(3):1342-8 - PubMed
  22. Neurobiol Dis. 2012 May;46(2):255-62 - PubMed
  23. PLoS One. 2013 Dec 18;8(12):e82606 - PubMed
  24. Expert Opin Drug Discov. 2015 Feb;10(2):125-39 - PubMed
  25. Cell Cycle. 2005 Oct;4(10):1377-81 - PubMed
  26. Proc Natl Acad Sci U S A. 2012 Oct 16;109 Suppl 2:17200-7 - PubMed
  27. Methods Mol Biol. 2008;448:187-212 - PubMed
  28. Neurologia. 2016 Nov - Dec;31(9):628-638 - PubMed
  29. Hum Mol Genet. 2011 Dec 15;20(24):4786-96 - PubMed
  30. Transl Psychiatry. 2013 Jun 11;3:e269 - PubMed

Publication Types